C4 Therapeutics (CCCC) director receives grant of 62,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

C4 Therapeutics director Donna Roy Grogan received a new stock option grant. She was awarded options covering 62,000 shares of Common Stock at an exercise price of $4.25 per share. These options are a compensation-related award, not an open-market stock purchase or sale.

The option will vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual meeting of stockholders, provided she continues serving on the Board through that date. Following this grant, her reported holdings in this option award total 62,000 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GROGAN DONNA ROY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 62,000 options Exercise price: $4.25 per share Underlying shares: 62,000 shares +3 more

6 metrics

Option grant size 62,000 options Stock Option (Right to Buy) granted to director

Exercise price $4.25 per share Conversion or exercise price of option

Underlying shares 62,000 shares Common Stock underlying the option

Expiration date June 23, 2036 Option expiration date

Post-transaction holdings in this award 62,000 derivative securities Total options following the grant

Vesting date trigger June 24, 2027 Earlier of this date or next annual meeting, subject to service

Key Terms

Stock Option (Right to Buy), Common Stock, Grant, award, or other acquisition, annual meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of the Issuer's stockholders financial

"earlier to occur of June 24, 2027 and the next annual meeting of the Issuer's stockholders"

Board financial

"subject to the recipient's continued service as a member of the Board"

A board is a group of elected people who oversee a company’s direction and management, like a steering committee that hires and evaluates the CEO, approves major deals, and sets broad policies. Investors care because the board’s decisions and oversight shape strategy, risk, dividend and takeover decisions, and legal protections for shareholders—so a strong, independent board can increase the chances of steady returns and protect against mismanagement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:26 PM Accepted by SEC EDGAR 06/26/2026 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROGAN DONNA ROY

(Last)

(First)

(Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		⁽¹⁾	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did C4 Therapeutics (CCCC) director Donna Roy Grogan report in this Form 4?

Donna Roy Grogan reported receiving a stock option grant for 62,000 shares of C4 Therapeutics Common Stock. The options are a compensation-related award, not a market trade, and give her the right to buy shares at a fixed exercise price.

How many C4 Therapeutics (CCCC) shares are covered by the new stock options?

The new stock option grant covers 62,000 shares of C4 Therapeutics Common Stock. This entire amount is reflected as derivative securities following the transaction, indicating the full award size reported in this Form 4 filing.

What is the exercise price and expiration for Donna Roy Grogan’s C4 Therapeutics options?

The stock options have an exercise price of $4.25 per share and an expiration date of June 23, 2036. This means she may buy shares at $4.25 any time after vesting until that expiration date.

When do Donna Roy Grogan’s C4 Therapeutics (CCCC) options vest?

The options vest and become exercisable in full on the earlier of June 24, 2027 or the next annual meeting of C4 Therapeutics stockholders. Vesting is contingent on her continued service on the Board through the applicable date.

Is this C4 Therapeutics Form 4 a stock purchase or sale in the market?

No, this Form 4 reports a grant of stock options as compensation, not a market purchase or sale. The transaction is coded as a grant/award acquisition of derivative securities rather than an open-market trade in C4 Therapeutics shares.